Therefore, anti-EGFR treatment may be considered in right-sided tumours if induction of tumour response for conversion therapy is the primary goal;22 to avoid a negative impact on OS, this approach requires an immediate switch of therapy in patients not responding to induction treatment. This evidence concerns the gene EGFR and neoplasm.